Investment case
Lisata Therapeutics, Inc.
LSTA · 2 developments mapped · last assessed 2026-09-17
Market Ontology has mapped 2 macro, policy, and market developments to Lisata Therapeutics, Inc. since 2026-09-17. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for LSTA yet, so no modelled value is shown. The LSTA valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run LSTA on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
Lisata Therapeutics, Inc. to Acquire Marea Therapeutics, Inc.
Direct impact from M&A transaction, dilution, and integration of new assets/liabilities.
· Moves future growth rates (revenue, pipeline success), cost synergies/dis synergies, risk profile of combined entity
What changed, by assumption
- 2026-09-17Lisata Therapeutics, Inc. to Acquire Marea Therapeutics, Inc.
- 2026-09-17Lisata Therapeutics, Inc. Follow-On — $225M
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-09-17 | Share count | Bullish | Issuance of common and preferred stock for Marea acquisition and concurrent PIPE will increase total as-converted share count to approximately 396.3 million. | 1.00 |
| 2026-09-17 | Share count | Bullish | Total number of shares of Lisata common stock (including shares underlying the Series C non-voting convertible preferred stock) will be approximately 396,315,542 following the Marea acquisition and PIPE. | 1.00 |
| 2026-09-17 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-09-17 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
| 2026-09-17 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-09-17 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-09-17 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
| 2026-07-03 | Net debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. | 0.70 |
| 2026-07-03 | Interest expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. | 0.70 |
| 2026-06-12 | Valuation multiple | Bullish | Target re-rates to bid premium until close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-17 | Lisata Therapeutics, Inc. to Acquire Marea Therapeutics, Inc. | mixed | 3-12m | 0.70 |
| 2026-09-17 | Lisata Therapeutics, Inc. Follow-On — $225M | mixed | 1-3m | 0.70 |